Adenoviral vector-mediated mRTVP-1 gene therapy for prostate cancer

Takefumi Satoh, Terry L. Timme, Takashi Saika, Shin Ebara, Guang Yang, Jianxiang Wang, Chengzhen Ren, Nobuyuki Kusaka, Vladimir Mouraviev, Timothy C. Thompson

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

We previously identified the mouse RTVP-1 (mRTVP-1; related to testes-specific, vespid, and pathogenesis proteins) gene as a direct target of p53 with proapoptotic activities in various cancer cell lines, including prostate cancer. To test the therapeutic potential of mRTVP-1 we constructed an adenoviral vector capable of efficient transduction and expression of mRTVP-1 (AdmRTVP-1) and used this vector in an orthotopic, metastatic mouse model of prostate cancer. A single intratumoral administration of AdmRTVP-1 gene therapy significantly reduced primary tumor wet weight compared with control Adβgal-injected tumors at two time points after injection with two different vector doses (p ≤ 0.01 at 7 and 14 days). Spontaneous metastasis to lung was also significantly reduced (p ≤ 0.02). Evaluation of treated tumors revealed increased apoptosis and lower microvessel density counts. In a rat aortic ring sprouting assay, AdmRTVP-1 inhibited endothelial cell sprouting compared with Adβgal, confirming its antiangiogenic activity. These therapeutic activities were associated with a significant increase in survival from 22.9 to 26.8 days (p = 0.003) in this aggressive model of prostate cancer. Interestingly, there were significant increases in the infiltration of tumor-associated macrophages, dendritic cells, and CD8+ T cells, which persisted at 14 days posttreatment in the AdmRTVP-1-treated tumors compared with Adβgal control-treated tumors. In addition, significantly increased natural killer and cytotoxic T lymphocyte activities were demonstrated in the mice with AdmRTVP-1-treated tumors. The unique therapeutic properties of AdmRTVP-1 gene therapy demonstrated in this study provide new opportunities for gene and immunotherapy of prostate cancer and potentially other malignancies.

Original languageEnglish
Pages (from-to)91-101
Number of pages11
JournalHuman Gene Therapy
Volume14
Issue number2
DOIs
Publication statusPublished - Jan 2003
Externally publishedYes

Fingerprint

Genetic Therapy
Prostatic Neoplasms
Neoplasms
Cytotoxic T-Lymphocytes
Microvessels
Tumor Burden
Immunotherapy
Dendritic Cells
Testis
Therapeutics
Endothelial Cells
Macrophages
Apoptosis
Neoplasm Metastasis
T-Lymphocytes
Cell Line
Lung
Injections
Genes
Proteins

ASJC Scopus subject areas

  • Genetics

Cite this

Satoh, T., Timme, T. L., Saika, T., Ebara, S., Yang, G., Wang, J., ... Thompson, T. C. (2003). Adenoviral vector-mediated mRTVP-1 gene therapy for prostate cancer. Human Gene Therapy, 14(2), 91-101. https://doi.org/10.1089/104303403321070793

Adenoviral vector-mediated mRTVP-1 gene therapy for prostate cancer. / Satoh, Takefumi; Timme, Terry L.; Saika, Takashi; Ebara, Shin; Yang, Guang; Wang, Jianxiang; Ren, Chengzhen; Kusaka, Nobuyuki; Mouraviev, Vladimir; Thompson, Timothy C.

In: Human Gene Therapy, Vol. 14, No. 2, 01.2003, p. 91-101.

Research output: Contribution to journalArticle

Satoh, T, Timme, TL, Saika, T, Ebara, S, Yang, G, Wang, J, Ren, C, Kusaka, N, Mouraviev, V & Thompson, TC 2003, 'Adenoviral vector-mediated mRTVP-1 gene therapy for prostate cancer', Human Gene Therapy, vol. 14, no. 2, pp. 91-101. https://doi.org/10.1089/104303403321070793
Satoh T, Timme TL, Saika T, Ebara S, Yang G, Wang J et al. Adenoviral vector-mediated mRTVP-1 gene therapy for prostate cancer. Human Gene Therapy. 2003 Jan;14(2):91-101. https://doi.org/10.1089/104303403321070793
Satoh, Takefumi ; Timme, Terry L. ; Saika, Takashi ; Ebara, Shin ; Yang, Guang ; Wang, Jianxiang ; Ren, Chengzhen ; Kusaka, Nobuyuki ; Mouraviev, Vladimir ; Thompson, Timothy C. / Adenoviral vector-mediated mRTVP-1 gene therapy for prostate cancer. In: Human Gene Therapy. 2003 ; Vol. 14, No. 2. pp. 91-101.
@article{efe5562f6be44c87bb3fcb8b48558d54,
title = "Adenoviral vector-mediated mRTVP-1 gene therapy for prostate cancer",
abstract = "We previously identified the mouse RTVP-1 (mRTVP-1; related to testes-specific, vespid, and pathogenesis proteins) gene as a direct target of p53 with proapoptotic activities in various cancer cell lines, including prostate cancer. To test the therapeutic potential of mRTVP-1 we constructed an adenoviral vector capable of efficient transduction and expression of mRTVP-1 (AdmRTVP-1) and used this vector in an orthotopic, metastatic mouse model of prostate cancer. A single intratumoral administration of AdmRTVP-1 gene therapy significantly reduced primary tumor wet weight compared with control Adβgal-injected tumors at two time points after injection with two different vector doses (p ≤ 0.01 at 7 and 14 days). Spontaneous metastasis to lung was also significantly reduced (p ≤ 0.02). Evaluation of treated tumors revealed increased apoptosis and lower microvessel density counts. In a rat aortic ring sprouting assay, AdmRTVP-1 inhibited endothelial cell sprouting compared with Adβgal, confirming its antiangiogenic activity. These therapeutic activities were associated with a significant increase in survival from 22.9 to 26.8 days (p = 0.003) in this aggressive model of prostate cancer. Interestingly, there were significant increases in the infiltration of tumor-associated macrophages, dendritic cells, and CD8+ T cells, which persisted at 14 days posttreatment in the AdmRTVP-1-treated tumors compared with Adβgal control-treated tumors. In addition, significantly increased natural killer and cytotoxic T lymphocyte activities were demonstrated in the mice with AdmRTVP-1-treated tumors. The unique therapeutic properties of AdmRTVP-1 gene therapy demonstrated in this study provide new opportunities for gene and immunotherapy of prostate cancer and potentially other malignancies.",
author = "Takefumi Satoh and Timme, {Terry L.} and Takashi Saika and Shin Ebara and Guang Yang and Jianxiang Wang and Chengzhen Ren and Nobuyuki Kusaka and Vladimir Mouraviev and Thompson, {Timothy C.}",
year = "2003",
month = "1",
doi = "10.1089/104303403321070793",
language = "English",
volume = "14",
pages = "91--101",
journal = "Human Gene Therapy",
issn = "1043-0342",
publisher = "Mary Ann Liebert Inc.",
number = "2",

}

TY - JOUR

T1 - Adenoviral vector-mediated mRTVP-1 gene therapy for prostate cancer

AU - Satoh, Takefumi

AU - Timme, Terry L.

AU - Saika, Takashi

AU - Ebara, Shin

AU - Yang, Guang

AU - Wang, Jianxiang

AU - Ren, Chengzhen

AU - Kusaka, Nobuyuki

AU - Mouraviev, Vladimir

AU - Thompson, Timothy C.

PY - 2003/1

Y1 - 2003/1

N2 - We previously identified the mouse RTVP-1 (mRTVP-1; related to testes-specific, vespid, and pathogenesis proteins) gene as a direct target of p53 with proapoptotic activities in various cancer cell lines, including prostate cancer. To test the therapeutic potential of mRTVP-1 we constructed an adenoviral vector capable of efficient transduction and expression of mRTVP-1 (AdmRTVP-1) and used this vector in an orthotopic, metastatic mouse model of prostate cancer. A single intratumoral administration of AdmRTVP-1 gene therapy significantly reduced primary tumor wet weight compared with control Adβgal-injected tumors at two time points after injection with two different vector doses (p ≤ 0.01 at 7 and 14 days). Spontaneous metastasis to lung was also significantly reduced (p ≤ 0.02). Evaluation of treated tumors revealed increased apoptosis and lower microvessel density counts. In a rat aortic ring sprouting assay, AdmRTVP-1 inhibited endothelial cell sprouting compared with Adβgal, confirming its antiangiogenic activity. These therapeutic activities were associated with a significant increase in survival from 22.9 to 26.8 days (p = 0.003) in this aggressive model of prostate cancer. Interestingly, there were significant increases in the infiltration of tumor-associated macrophages, dendritic cells, and CD8+ T cells, which persisted at 14 days posttreatment in the AdmRTVP-1-treated tumors compared with Adβgal control-treated tumors. In addition, significantly increased natural killer and cytotoxic T lymphocyte activities were demonstrated in the mice with AdmRTVP-1-treated tumors. The unique therapeutic properties of AdmRTVP-1 gene therapy demonstrated in this study provide new opportunities for gene and immunotherapy of prostate cancer and potentially other malignancies.

AB - We previously identified the mouse RTVP-1 (mRTVP-1; related to testes-specific, vespid, and pathogenesis proteins) gene as a direct target of p53 with proapoptotic activities in various cancer cell lines, including prostate cancer. To test the therapeutic potential of mRTVP-1 we constructed an adenoviral vector capable of efficient transduction and expression of mRTVP-1 (AdmRTVP-1) and used this vector in an orthotopic, metastatic mouse model of prostate cancer. A single intratumoral administration of AdmRTVP-1 gene therapy significantly reduced primary tumor wet weight compared with control Adβgal-injected tumors at two time points after injection with two different vector doses (p ≤ 0.01 at 7 and 14 days). Spontaneous metastasis to lung was also significantly reduced (p ≤ 0.02). Evaluation of treated tumors revealed increased apoptosis and lower microvessel density counts. In a rat aortic ring sprouting assay, AdmRTVP-1 inhibited endothelial cell sprouting compared with Adβgal, confirming its antiangiogenic activity. These therapeutic activities were associated with a significant increase in survival from 22.9 to 26.8 days (p = 0.003) in this aggressive model of prostate cancer. Interestingly, there were significant increases in the infiltration of tumor-associated macrophages, dendritic cells, and CD8+ T cells, which persisted at 14 days posttreatment in the AdmRTVP-1-treated tumors compared with Adβgal control-treated tumors. In addition, significantly increased natural killer and cytotoxic T lymphocyte activities were demonstrated in the mice with AdmRTVP-1-treated tumors. The unique therapeutic properties of AdmRTVP-1 gene therapy demonstrated in this study provide new opportunities for gene and immunotherapy of prostate cancer and potentially other malignancies.

UR - http://www.scopus.com/inward/record.url?scp=0037260825&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037260825&partnerID=8YFLogxK

U2 - 10.1089/104303403321070793

DO - 10.1089/104303403321070793

M3 - Article

VL - 14

SP - 91

EP - 101

JO - Human Gene Therapy

JF - Human Gene Therapy

SN - 1043-0342

IS - 2

ER -